AffyImmune’s lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T-cell therapy. AIC100’s CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity and may also be used as a safety and activation switch using several FDA approved drugs.
Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies.
AffyImmune is developing AIC100 for ARTC, gastric cancer and TNBC. An IND for a Phase I clinical trial of our lead compound in patients with ARTC has been submitted to the FDA and approved for patient enrollment.
Dual-Targeted and Novel Affinity-Tuned CARs
We are applying our unique affinity-tuning technology to develop dual-targeted affinity-tuned CAR T-cell therapies, as well as generating novel affinity-tuned CARs. These programs are currently in discovery phase.